Literature DB >> 17448954

Risk assessment in haematopoietic stem cell transplantation: histocompatibility.

Effie W Petersdorf1.   

Abstract

Consideration of potential donors for transplantation includes a rigorous assessment of the availability and HLA-match status of family members, and the identification of suitable unrelated donors when related donors are not available. Because HLA gene products provoke host-versus-graft and graft-versus-host alloimmune responses, HLA matching serves a critical preventive role in lowering risks of graft failure and graft-versus-host disease (GVHD). At the same time, graft-versus-leukemia effects associated with HLA mismatching may provide an immunological means to lower the recurrence of post-transplant disease in high-risk patients. The definition of a suitable allogeneic donor is ever changing, shaped not only by current typing technology for the known HLA genes but also by the specific transplant procedure. Increased safety of alternative donor hematopoietic cell transplantation (HCT) has been achieved in part through advances in the field of immunogenetics. Increased availability of HCT through the use of HLA-mismatched related and unrelated donors is feasible with a more complete understanding of permissible HLA mismatches and the role of NK-KIR genes in transplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17448954      PMCID: PMC3680359          DOI: 10.1016/j.beha.2006.09.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  100 in total

1.  Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors.

Authors:  Martin Bornhäuser; Rainer Schwerdtfeger; Hilmar Martin; Karl-Heinz Frank; Catrin Theuser; Gerhard Ehninger
Journal:  Blood       Date:  2004-04-01       Impact factor: 22.113

2.  Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia.

Authors:  S Hongeng; R A Krance; L C Bowman; D K Srivastava; J M Cunningham; E M Horwitz; M K Brenner; H E Heslop
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

3.  Transplantation of filgrastim-mobilized peripheral blood stem cells from HLA-identical sibling or alternative family donors in patients with hematologic malignancies: a prospective comparison on clinical outcome, immune reconstitution, and hematopoietic chimerism.

Authors:  D W Beelen; H D Ottinger; A Elmaagacli; B Scheulen; O Basu; B Kremens; W Havers; H Grosse-Wilde; U W Schaefer
Journal:  Blood       Date:  1997-12-15       Impact factor: 22.113

4.  HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry.

Authors:  M Mori; P G Beatty; M Graves; K M Boucher; E L Milford
Journal:  Transplantation       Date:  1997-10-15       Impact factor: 4.939

5.  Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors.

Authors:  N M Valiante; M Uhrberg; H G Shilling; K Lienert-Weidenbach; K L Arnett; A D'Andrea; J H Phillips; L L Lanier; P Parham
Journal:  Immunity       Date:  1997-12       Impact factor: 31.745

6.  Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient.

Authors:  E W Petersdorf; T A Gooley; C Anasetti; P J Martin; A G Smith; E M Mickelson; A E Woolfrey; J A Hansen
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

7.  Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program.

Authors:  T Sasazuki; T Juji; Y Morishima; N Kinukawa; H Kashiwabara; H Inoko; T Yoshida; A Kimura; T Akaza; N Kamikawaji; Y Kodera; F Takaku
Journal:  N Engl J Med       Date:  1998-10-22       Impact factor: 91.245

8.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.

Authors:  F Aversa; A Tabilio; A Velardi; I Cunningham; A Terenzi; F Falzetti; L Ruggeri; G Barbabietola; C Aristei; P Latini; Y Reisner; M F Martelli
Journal:  N Engl J Med       Date:  1998-10-22       Impact factor: 91.245

9.  Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients.

Authors:  J Mehta; S Singhal; A P Gee; K-Y Chiang; K Godder; F van Rhee Fv; S DeRienzo; W O'Neal; L Lamb; P J Henslee-Downey
Journal:  Bone Marrow Transplant       Date:  2004-02       Impact factor: 5.483

10.  The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.

Authors:  A Bishara; D De Santis; C C Witt; C Brautbar; F T Christiansen; R Or; A Nagler; S Slavin
Journal:  Tissue Antigens       Date:  2004-03
View more
  15 in total

Review 1.  HLA testing in the molecular diagnostic laboratory.

Authors:  Kathleen Madden; Devon Chabot-Richards
Journal:  Virchows Arch       Date:  2018-12-04       Impact factor: 4.064

2.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

3.  Position 156 influences the peptide repertoire and tapasin dependency of human leukocyte antigen B*44 allotypes.

Authors:  Soumya Badrinath; Philippa Saunders; Trevor Huyton; Susanne Aufderbeck; Oliver Hiller; Rainer Blasczyk; Christina Bade-Doeding
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

4.  Association of functional polymorphisms of the transforming growth factor B1 gene with survival and graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation.

Authors:  Mariano Berro; Neema P Mayor; Hazael Maldonado-Torres; Louise Cooke; Gustavo Kusminsky; Steven G E Marsh; J Alejandro Madrigal; Bronwen E Shaw
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

5.  Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model.

Authors:  Sandra Lange; Simone Altmann; Bettina Brandt; Carsten Adam; Franziska Riebau; Heike Vogel; Volker Weirich; Inken Hilgendorf; Rainer Storb; Mathias Freund; Christian Junghanss
Journal:  Exp Hematol       Date:  2009-01       Impact factor: 3.084

6.  The impact of HLA matching on unrelated donor hematopoietic stem cell transplantation in Korean children.

Authors:  Meerim Park; Kyung Nam Koh; Bo Eun Kim; Ho Joon Im; Kyung Duk Park; Hyoung Jin Kang; Hee Young Shin; Hyo Seop Ahn; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo; Hyeon Jin Park; Byung-Kiu Park; Jong Jin Seo
Journal:  Korean J Hematol       Date:  2011-03-15

7.  A Micropolymorphism Altering the Residue Triad 97/114/156 Determines the Relative Levels of Tapasin Independence and Distinct Peptide Profiles for HLA-A(*)24 Allotypes.

Authors:  Soumya Badrinath; Heike Kunze-Schumacher; Rainer Blasczyk; Trevor Huyton; Christina Bade-Doeding
Journal:  J Immunol Res       Date:  2014-12-04       Impact factor: 4.818

8.  NOD2 Polymorphisms and Their Impact on Haematopoietic Stem Cell Transplant Outcome.

Authors:  Neema P Mayor; Bronwen E Shaw; J Alejandro Madrigal; Steven G E Marsh
Journal:  Bone Marrow Res       Date:  2012-10-18

9.  Immune reconstitution and graft-versus-host reactions in rat models of allogeneic hematopoietic cell transplantation.

Authors:  Severin Zinöcker; Ralf Dressel; Xiao-Nong Wang; Anne M Dickinson; Bent Rolstad
Journal:  Front Immunol       Date:  2012-11-30       Impact factor: 7.561

Review 10.  Acute graft versus host disease.

Authors:  David A Jacobsohn; Georgia B Vogelsang
Journal:  Orphanet J Rare Dis       Date:  2007-09-04       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.